Scott Requadt - Net Worth and Insider Trading

Scott Requadt Net Worth

The estimated net worth of Scott Requadt is at least $260,698 dollars as of 2024-11-13. Scott Requadt is the CEO of Talaris Therapeutics Inc and owns about 95,845 shares of Talaris Therapeutics Inc (TALS) stock worth over $260,698. Details can be seen in Scott Requadt's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Scott Requadt has not made any transactions after 2022-07-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Scott Requadt

To

Scott Requadt Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Scott Requadt owns 6 companies in total, including ESSA Pharma Inc (EPIX) , VBI Vaccines Inc (VBIVQ) , and Entasis Therapeutics Holdings Inc (ETTX) among others .

Click here to see the complete history of Scott Requadt’s form 4 insider trades.

Insider Ownership Summary of Scott Requadt

Ticker Comapny Transaction Date Type of Owner
EPIX ESSA Pharma Inc 2020-10-01 director
VBIVQ VBI Vaccines Inc 2016-12-31 director
ETTX Entasis Therapeutics Holdings Inc 2018-09-25 10 percent owner
LIMIT LIMIT 2018-07-02 10 percent owner
LIMIT LIMIT 2018-06-20 director
LIMIT LIMIT 2022-07-29 director & See Remarks

Scott Requadt Latest Holdings Summary

Scott Requadt currently owns a total of 1 stock. Scott Requadt owns 95,845 shares of Talaris Therapeutics Inc (TALS) as of July 29, 2022, with a value of $260,698.

Latest Holdings of Scott Requadt

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TALS Talaris Therapeutics Inc 2022-07-29 95,845 2.72 260,698

Holding Weightings of Scott Requadt


Scott Requadt Form 4 Trading Tracker

According to the SEC Form 4 filings, Scott Requadt has made a total of 3 transactions in Talaris Therapeutics Inc (TALS) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Talaris Therapeutics Inc is the acquisition of 3,938 shares on July 29, 2022, which cost Scott Requadt around $167,374.

Insider Trading History of Scott Requadt

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Scott Requadt Trading Performance

GuruFocus tracks the stock performance after each of Scott Requadt's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Scott Requadt is -63.55%. GuruFocus also compares Scott Requadt's trading performance to market benchmark return within the same time period. The performance of stocks bought by Scott Requadt within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Scott Requadt's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Scott Requadt

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -13.55 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -14.11 LIMIT LIMIT LIMIT LIMIT LIMIT

Scott Requadt Ownership Network

Ownership Network List of Scott Requadt

No Data

Ownership Network Relation of Scott Requadt

Insider Network Chart

Scott Requadt Owned Company Details

What does ESSA Pharma Inc do?

Who are the key executives at ESSA Pharma Inc?

Scott Requadt is the director of ESSA Pharma Inc. Other key executives at ESSA Pharma Inc include 10 percent owner Biotech Growth N V , Chief Operating Officer Peter Virsik , and director & Chief Executive Officer David Ross Parkinson .

ESSA Pharma Inc (EPIX) Insider Trades Summary

Over the past 18 months, Scott Requadt made no insider transaction in ESSA Pharma Inc (EPIX). Other recent insider transactions involving ESSA Pharma Inc (EPIX) include a net sale of 81,945 shares made by Peter Virsik , a net purchase of 99,730 shares made by Franklin M Berger , and a net sale of 7,879,583 shares made by Biotech Growth N V .

In summary, during the past 3 months, insiders sold 7,883,053 shares of ESSA Pharma Inc (EPIX) in total and bought 0 shares, with a net sale of 7,883,053 shares. During the past 18 months, 7,961,528 shares of ESSA Pharma Inc (EPIX) were sold and 108,953 shares were bought by its insiders, resulting in a net sale of 7,852,575 shares.

ESSA Pharma Inc (EPIX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

ESSA Pharma Inc Insider Transactions

No Available Data

Scott Requadt Mailing Address

Above is the net worth, insider trading, and ownership report for Scott Requadt. You might contact Scott Requadt via mailing address: 101 Main Street, Suite 1210, Cambridge Ma 02142.